Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson Posts 11-Percent Rise in Fiscal Q2 Revenue as R&D Spend Falls and Profit Jumps

NEW YORK (GenomeWeb News) — Becton Dickinson today said that fiscal second-quarter revenues rose 11 percent as R&D spending decreased 32 percent and profit swelled 57 percent.
 
Total receipts for the three months ended March 31 increased to $1.6 billion from $1.4 billion year over year.
 
BD said revenues from its Diagnostics segment increased 11 percent to $473 million, while Biosciences revenue rose 13 percent to $258.5 million. Revenue from the Medical segment rose 10 percent to $844.1 million.  
 
The company also said that Tripath Imaging, which BD acquired late last year, contributed $27 million in second quarter sales.
  
R&D spending for the quarter decreased to $86.7 million from $127.7 million year over year.
 
Net profits for the quarter increased to $242.5 million from $154.1 million in the year-ago period.
 
The company did not disclose its balance sheet for the period.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.